Journal of Pharmacology and Pharmacotherapeutics

: 2012  |  Volume : 3  |  Issue : 4  |  Page : 333--335

Insulin glargine overdose

Fatma Sari Dogan1, Ozge Ecmel Onur2, Arzu Denizbasi Altinok2, Ozlem Guneysel3 
1 Department of Emergency Medicine, Goztepe Training and Research Hospital, Istanbul, Turkey
2 Marmara University School of Medicine, Istanbul, Turkey
3 Emergency Medicine Clinic, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Emergency Medicine Clinic Istanbul, Turkey

Correspondence Address:
Fatma Sari Dogan
Goztepe Training and Research Hospital, Doktor Erkin Cad. Kadiköy/Istanbul

Insulin glargine is a long acting novel recombinant human insulin analogue indicated to improve glycemic control, in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The time course of action of insulins including insulin glargine may vary between individuals and/or within the same individual. Insulin glargine is given as a 24-h dosing regimen and has no documented half-life or peak effect. Hypoglycemia is the most common adverse effect of insulin, including insulin glargine. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations. We present a case of a 76-year-old male insulin-dependent diabetic patient with refractory hypoglycemia secondary to an intentional overdose of insulin glargine. We would like to highlight the necessity of prolonging IV glucose infusion, for a much longer period than expected from pharmacokinetic properties of these insulin analogues after intentional massive overdose.

How to cite this article:
Dogan FS, Onur OE, Altinok AD, Guneysel O. Insulin glargine overdose.J Pharmacol Pharmacother 2012;3:333-335

How to cite this URL:
Dogan FS, Onur OE, Altinok AD, Guneysel O. Insulin glargine overdose. J Pharmacol Pharmacother [serial online] 2012 [cited 2020 Sep 19 ];3:333-335
Available from:;year=2012;volume=3;issue=4;spage=333;epage=335;aulast=Dogan;type=0